Abstract: Systems and methods are described for treatment and/or prevention of a metabolic disorder and/or another medical condition in a patient (e.g., a feline) by administering to the patient a liquid pharmaceutical composition, preferably including one or more SGLT-2 inhibitor compound(s), via a delivery system that includes a syringe. The syringe includes features that facilitate easy, safe and effective doses of small volumetric amounts of the liquid pharmaceutical composition to the patient during administration.

Abstract: The invention relates to novel aqueous pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more solubilizing agents as well as corresponding processes of manufacturing such aqueous pharmaceutical compositions and their medical uses.

Abstract: The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.

Abstract: The invention relates to a system composed of an inhaler and a capsule, preferably intended for single use. The capsule contains a preferably powdered pharmaceutical preparation which, for inhalation, is expelled from the capsule through at least one hole. The capsule comprises as capsule elements a capsule cap and a capsule body, at least one of which comprises at least one prefabricated hole. The prefabricated hole in the capsule is sealed off in the transporting state of the system and is open in the usage state. The hole is exposed by actuation of a pulling mechanism. Prior to this the hole is closed off by a capsule receptacle or a film. In one embodiment the capsule may be present in two different states, for example in different insertion positions of the capsule elements. In the first state the prefabricated hole is closed off and in the second it is exposed. Also shown is an inhaler suitable as a disposable product, which is manufactured from thermoformed parts or from blister film.

Abstract: The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.

Abstract: The invention relates to a capsule for receiving a preferably powdered pharmaceutical preparation and an inhaler in which, for inhalation, the preparation is expelled from the capsule through at least one hole. A capsule according to the invention comprises as capsule elements a capsule cap and a capsule body, at least one of which comprises at least one prefabricated hole. Systems according to the invention comprising inhalers and capsules are described, in which the prefabricated hole in the capsule is sealed off in the transporting state of the system and is open in the usage state. The hole is exposed by actuation of a pushing or pulling mechanism. Prior to this the hole is closed off by part of the capsule itself or by a capsule receptacle belonging to the inhaler. In one embodiment the capsule may be present in two different states, for example in different insertion positions of the capsule elements. In the first state the prefabricated hole is closed off and in the second it is exposed.

Abstract: The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.

Abstract: A spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X? is a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, and iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, with the exception of amino carboxylic acids, preferably fumaric acid, oxalic acid, or diacetic acid, and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, ?-hydroxycaprylic acid or gluconic acid.

Abstract: The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.

Abstract: A spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X? is a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, and iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, with the exception of amino carboxylic acids, to preferably fumaric acid, oxalic acid, or diacetic acid, and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, ?-hydroxycaprylic acid or gluconic acid.

Abstract: The invention relates to manufacturing processes for preparing inhalable powders, and to the stable crystalline inhalable powders prepared by this process. Similarly, the invention relates to the use of these inhalable powders for preparing a medicament for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

Abstract: The invention relates to a system composed of an inhaler and a capsule, preferably intended for single use. The capsule contains a preferably powdered pharmaceutical preparation which, for inhalation, is expelled from the capsule through at least one hole. The capsule comprises as capsule elements a capsule cap and a capsule body, at least one of which comprises at least one prefabricated hole. The prefabricated hole in the capsule is sealed off in the transporting state of the system and is open in the usage state. The hole is exposed by actuation of a pulling mechanism. Prior to this the hole is closed off by a capsule receptacle or a film. In one embodiment the capsule may be present in two different states, for example in different insertion positions of the capsule elements. In the first state the prefabricated hole is closed off and in the second it is exposed. Also shown is an inhaler suitable as a disposable product, which is manufactured from thermoformed parts or from blister film.

Abstract: The invention relates to a capsule for receiving a preferably powdered pharmaceutical preparation and an inhaler in which, for inhalation, the preparation is expelled from the capsule through at least one hole. A capsule according to the invention comprises as capsule elements a capsule cap and a capsule body, at least one of which comprises at least one prefabricated hole. Systems according to the invention comprising inhalers and capsules are described, in which the prefabricated hole in the capsule is sealed off in the transporting state of the system and is open in the usage state. The hole is exposed by actuation of a pushing or pulling mechanism. Prior to this the hole is closed off by part of the capsule itself or by a capsule receptacle belonging to the inhaler. In one embodiment the capsule may be present in two different states, for example in different insertion positions of the capsule elements. In the first state the prefabricated hole is closed off and in the second it is exposed.

Abstract: The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X? represents a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, with the exception of amino carboxylic acids, preferably fumaric acid, oxalic acid, or diacetic acid, and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, ?-hydroxycaprylic acid or gluconic acid. The invention also relates to a method for producing said formulation.

Abstract: The invention relates to manufacturing processes for preparing inhalable powders, and to the stable crystalline inhalable powders prepared by this process. Similarly, the invention relates to the use of these inhalable powders for preparing a medicament for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

Abstract: The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X? represents a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, with the exception of amino carboxylic acids, preferably fumaric acid, oxalic acid, or diacetic acid, and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, ?-hydroxycaprylic acid or gluconic acid.

Abstract: The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) a compound of formula 1, in which A represents a group selected from (I), (II) or (III), R and R? each representing hydrogen or in combination form a group selected from a single bond, —CH2— and —O—, and in which X? represents a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, preferably fumaric acid, oxalic acid, diacetic acid or a sterically demanding amino acid and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, ?-hydroxycaprylic acid or gluconic acid.

Abstract: The invention relates to an inhalation powder for treating migraine, containing the CGRP antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I as the active substance base in the form of spherically nanostructured microparticles, and a process for the manufacture thereof.

Abstract: The invention relates to salts of the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2-(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I, the preparation thereof, a process for preparing an inhalation powder containing a salt of the active substance BIBN4096 as well as the inhalation powders which can be obtained by the process.

Abstract: The invention relates to salts of the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I, the preparation thereof, a process for preparing an inhalation powder containing a salt of the active substance BIBN4096 as well as the inhalation powders which can be obtained by the process.